Form D · Biotechnology
CiVi Biopharma Holdings, Inc.
Chevy Chase, MD · CIK 0001740380
Offering snapshot reported Dec 30, 2020 · SEC filing
- Reported sold
- $27.5M Offering amount: $27.5M
- Investors reported
- 9 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Nov 18, 2020 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 30, 2020 | Initial | $27,456,172 | No comparison | 9 | SEC filing |
| May 22, 2018 | Initial | $49,000,000 | No comparison | 6 | SEC filing |
Offering details
- Securities
- Equity, Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-384757
A portion of the proceeds were satisfied by cancellation of indebtedness.
Preferred Stock can convert to underlying shares of Common Stock.
Source: Form D, filed Dec 30, 2020. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Aaron Davis | Director |
| Christopher Fuglesang | Director |
| Shalom Jacobovitz | Director, Executive |
| Carole Nuechterlein | Director |
| Henrik Oerum | Director |
| Matthew Pietras | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
5425 Wisconsin Ave.
Chevy Chase, MD, 20815
Chevy Chase, MD, 20815